Regeneron Files 2025 Proxy Statement on Executive Compensation

Ticker: REGN · Form: DEF 14A · Filed: 2025-04-29T00:00:00.000Z

Sentiment: neutral

Topics: proxy-statement, executive-compensation, corporate-governance

TL;DR

Regeneron's 2025 proxy statement is out, detailing exec pay for 2024. Vote wisely.

AI Summary

Regeneron Pharmaceuticals, Inc. filed its Definitive Proxy Statement (DEF 14A) on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity awards granted to its PEO (Principal Executive Officer) and Non-PEO NEOs (Named Executive Officers) for the fiscal year 2024. It also provides information on the company's fiscal years 2020 through 2024 for comparative purposes.

Why It Matters

This filing provides shareholders with crucial information regarding how Regeneron's top executives are compensated, impacting decisions on executive pay and corporate governance.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and is not indicative of immediate financial risk.

Key Numbers

2024 — Fiscal Year (Primary year for executive compensation details in this filing.)
2020-2024 — Comparative Fiscal Years (Range of fiscal years for which data is presented for comparison.)

Key Players & Entities

REGENERON PHARMACEUTICALS, INC. (company) — Filer of the DEF 14A
0000872589 (company) — Central Index Key for Regeneron Pharmaceuticals, Inc.
20250429 (date) — Filing date of the DEF 14A
2024-12-31 (date) — Fiscal year end for which compensation details are provided

FAQ

What is the primary purpose of this DEF 14A filing?

The primary purpose is to provide shareholders with information regarding executive compensation, board of directors, and other corporate governance matters, including details on equity awards for the fiscal year ending December 31, 2024.

When was this Definitive Proxy Statement filed?

This Definitive Proxy Statement was filed on April 29, 2025.

Which fiscal year's executive compensation is detailed in this filing?

The filing details executive compensation for the fiscal year ending December 31, 2024, with comparative data for fiscal years 2020 through 2023.

What type of compensation details are highlighted for PEO and Non-PEO NEOs?

The filing highlights equity awards, including those granted in the covered year, year-end values of outstanding and unvested awards, and changes in the fair value of prior year grants.

What is Regeneron Pharmaceuticals, Inc.'s Central Index Key (CIK)?

Regeneron Pharmaceuticals, Inc.'s Central Index Key (CIK) is 0000872589.

From the Filing

0001308179-25-000518.txt : 20250429 0001308179-25-000518.hdr.sgml : 20250429 20250429060343 ACCESSION NUMBER: 0001308179-25-000518 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 130 CONFORMED PERIOD OF REPORT: 20250613 FILED AS OF DATE: 20250429 DATE AS OF CHANGE: 20250429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 25882463 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 DEF 14A 1 regn013211-def14a.htm DEFINITIVE PROXY STATEMENT REGENERON PHARMACEUTICALS, INC. - DEF 14A false 0000872589 DEF 14A 0000872589 2024-01-01 2024-12-31 0000872589 2023-01-01 2023-12-31 0000872589 2022-01-01 2022-12-31 0000872589 2021-01-01 2021-12-31 0000872589 2020-01-01 2020-12-31 0000872589 ecd:PeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2024-01-01 2024-12-31 0000872589 ecd:PeoMember ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember 2024-01-01 2024-12-31 0000872589 ecd:NonPeoNeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2024-01-01 2024-12-31 0000872589 ecd:NonPeoNeoMember ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember 2024-01-01 2024-12-31 0000872589 ecd:PeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2024-01-01 2024-12-31 0000872589 ecd:PeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2024-01-01 2024-12-31 0000872589 ecd:PeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2024-01-01 2024-12-31 0000872589 ecd:PeoMember ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2024-01-01 2024-12-31 0000872589 ecd:PeoMember ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2024-01-01 2024-12-31 0000872589 ecd:PeoMember ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember 2024-01-01 2024-12-31 0000872589 ecd:NonPeoNeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2024-01-01 2024-12-31 0000872589 ecd:NonPeoNeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2024-01-01 2024-12-31 0000872589 ecd:NonPeoNeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2024-01-01 2024-12-31 0000872589 ecd:NonPeoNeoMember ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2024-01-01 2024-12-31 0000872589 ecd:NonPeoNeoMember ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2024-01-01 2024-12-31 0000872589 ecd:NonPeoNeoMember ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember 2024-01-01 2024-12-31 0000872589 1 2024-01-01 2024-12-31 0000872589 5 2024-01-01 2024-12-31 0000872589 2 2024-01-01 2024-12-31 0000872589 6 2024-01-01 2024-12-31 0000872589 3 2024-01-01 2024-12-31 0000872589 7 2024-01-01 2024-12-31 0000872589 4 2024-01-01 2024-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, DC 20549   SCHEDULE 14A   PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.     )     Filed by the Registrant   Filed by a Party other than the Registrant   Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12   REGENERON PHARMACEUTICALS, INC.     (Name of Registrant as